Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

(2014) J Murray et al.   BRITISH JOURNAL OF CANCER

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

(2014) F. Lin et al.   CLINICAL CANCER RESEARCH

Targeting the BRCA1/2 Tumor Suppressors

(2014) Eliot Rosen et al.   CURRENT DRUG TARGETS

High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival

(2013) Akimitsu Yamada et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

(2013) Ruth Plummer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

(2013) F. Lin et al.   CLINICAL CANCER RESEARCH

Liquid chromatography–tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma

(2013) Rolf W. Sparidans et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Role of PARP Inhibitors in Cancer Biology and Therapy

(2012) D. Davar et al.   CURRENT MEDICINAL CHEMISTRY

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar

(2012) Selvi Durmus et al.   MOLECULAR PHARMACEUTICS

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

(2011) B. Poller et al.   DRUG METABOLISM AND DISPOSITION

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

(2011) Seng Chuan Tang et al.   INTERNATIONAL JOURNAL OF CANCER

P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration

(2011) D. Iusuf et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Unknown

(2011) Mary Leung et al.   MOLECULAR MEDICINE

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood−Brain Barrier

(2011) Birk Poller et al.   MOLECULAR PHARMACEUTICS

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

(2011) Kunal S. Taskar et al.   PHARMACEUTICAL RESEARCH

Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

(2010) P. R. Lockman et al.   CLINICAL CANCER RESEARCH

Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

(2010) H. Kodaira et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters

(2010) J. S. Lagas et al.   MOLECULAR PHARMACOLOGY

Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets

(2010) Anthony J. Chalmers et al.   SEMINARS IN RADIATION ONCOLOGY

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

(2009) J. S. Lagas et al.   CLINICAL CANCER RESEARCH

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide

(2009) J. S. Lagas et al.   CLINICAL CANCER RESEARCH

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice

(2009) L. Zhou et al.   DRUG METABOLISM AND DISPOSITION

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

(2009) Yvette Drew et al.   DRUG RESISTANCE UPDATES

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial

(2008) B. C. Pestalozzi et al.   ANNALS OF ONCOLOGY

P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin

(2008) J. S. Lagas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)

(2008) J. W. Polli et al.   DRUG METABOLISM AND DISPOSITION

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

(2008) Roos L. Oostendorp et al.   INVESTIGATIONAL NEW DRUGS

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA